

# Angelo Antonini

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7679200/angelo-antonini-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

552  
papers

27,066  
citations

85  
h-index

139  
g-index

623  
ext. papers

31,023  
ext. citations

4.9  
avg, IF

6.84  
L-index

#	Paper	IF	Citations
552	The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. <i>Movement Disorders</i> , <b>2009</b> , 24, 1641-9	7	919
551	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , <b>2017</b> , 32, 853-864	7	840
550	Valvular heart disease and the use of dopamine agonists for Parkinson's disease. <i>New England Journal of Medicine</i> , <b>2007</b> , 356, 39-46	59.2	705
549	Requirement for subplate neurons in the formation of thalamocortical connections. <i>Nature</i> , <b>1990</b> , 347, 179-81	50.4	505
548	Rapid remodeling of axonal arbors in the visual cortex. <i>Science</i> , <b>1993</b> , 260, 1819-21	33.3	440
547	Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. <i>Lancet Neurology</i> , <b>2014</b> , 13, 141-9	24.1	425
546	Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. <i>Nature Genetics</i> , <b>2011</b> , 43, 699-705	36.3	386
545	miR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition. <i>Cell Death and Differentiation</i> , <b>2011</b> , 18, 1628-39	12.7	352
544	EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. <i>European Journal of Neurology</i> , <b>2013</b> , 20, 16-34	6	299
543	Patterns of regional brain activation associated with different forms of motor learning. <i>Brain Research</i> , <b>2000</b> , 871, 127-45	3.7	299
542	Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. <i>Brain</i> , <b>1996</b> , 119 ( Pt 6), 2085-95	11.2	280
541	Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. <i>Neurology</i> , <b>2005</b> , 65, 87-95	6.5	276
540	Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). <i>European Neuropsychopharmacology</i> , <b>1997</b> , 7, 9-24	1.2	271
539	Functional brain networks in DYT1 dystonia. <i>Annals of Neurology</i> , <b>1998</b> , 44, 303-12	9.4	263
538	Anatomical correlates of functional plasticity in mouse visual cortex. <i>Journal of Neuroscience</i> , <b>1999</b> , 19, 4388-406	6.6	261
537	Parkinson's disease: the non-motor issues. <i>Parkinsonism and Related Disorders</i> , <b>2011</b> , 17, 717-23	3.6	258
536	Development of individual geniculocortical arbors in cat striate cortex and effects of binocular impulse blockade. <i>Journal of Neuroscience</i> , <b>1993</b> , 13, 3549-73	6.6	223

535	Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. <i>Movement Disorders</i> , <b>2007</b> , 22, 1145-9	7	218
534	Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. <i>Journal of Neurology</i> , <b>2006</b> , 253, 601-7	5.5	209
533	Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. <i>Lancet Neurology</i> , <b>2007</b> , 6, 826-9	24.1	200
532	Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. <i>Movement Disorders</i> , <b>2009</b> , 24, 1468-74	7	191
531	Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [ <sup>11</sup> C]raclopride. <i>Movement Disorders</i> , <b>1997</b> , 12, 33-8	7	191
530	Alpha 6 beta 4 and alpha 6 beta 1 integrins associate with ErbB-2 in human carcinoma cell lines. <i>Experimental Cell Research</i> , <b>1997</b> , 236, 76-85	4.2	187
529	Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. <i>Archives of Neurology</i> , <b>2008</b> , 65, 1191-4		186
528	Role of DAT-SPECT in the diagnostic work up of parkinsonism. <i>Movement Disorders</i> , <b>2007</b> , 22, 1229-38	7	180
527	[ <sup>11</sup> C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors. <i>Neurology</i> , <b>1994</b> , 44, 1325-9	6.5	180
526	Parkinson's disease tremor-related metabolic network: characterization, progression, and treatment effects. <i>NeuroImage</i> , <b>2011</b> , 54, 1244-53	7.9	176
525	Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. <i>Brain</i> , <b>1997</b> , 120 ( Pt 12), 2187-95	11.2	169
524	EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. <i>Movement Disorders</i> , <b>2015</b> , 30, 510-6	7	161
523	Levodopa in the treatment of Parkinson's disease: an old drug still going strong. <i>Clinical Interventions in Aging</i> , <b>2010</b> , 5, 229-38	4	160
522	Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. <i>Archives of Neurology</i> , <b>1995</b> , 52, 1183-90		155
521	The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life. <i>Journal of Neurology</i> , <b>2012</b> , 259, 2621-31	5.5	154
520	Effect of age on D2 dopamine receptors in normal human brain measured by positron emission tomography and <sup>11</sup> C-raclopride. <i>Archives of Neurology</i> , <b>1993</b> , 50, 474-80		154
519	Gender-related differences in the burden of non-motor symptoms in Parkinson's disease. <i>Journal of Neurology</i> , <b>2012</b> , 259, 1639-47	5.5	153
518	Positron emission tomographic studies in restless legs syndrome. <i>Movement Disorders</i> , <b>1999</b> , 14, 141-5	7	149

517	Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group. <i>Movement Disorders</i> , <b>2014</b> , 29, 857-67	7	148
516	T2 relaxation time in patients with Parkinson's disease. <i>Neurology</i> , <b>1993</b> , 43, 697-700	6.5	146
515	A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. <i>Lancet Neurology</i> , <b>2009</b> , 8, 929-37	24.1	145
514	The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. <i>Journal of Medical Genetics</i> , <b>2005</b> , 42, e65	5.8	141
513	The metabolic anatomy of Tourette's syndrome. <i>Neurology</i> , <b>1997</b> , 48, 927-34	6.5	140
512	The metabolic topography of essential blepharospasm: a focal dystonia with general implications. <i>Neurology</i> , <b>2000</b> , 55, 673-7	6.5	137
511	Storage characteristics of cathodes for Li-ion batteries. <i>Electrochimica Acta</i> , <b>1996</b> , 41, 2683-2689	6.7	137
510	Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. <i>European Journal of Human Genetics</i> , <b>2006</b> , 14, 322-31	5.3	134
509	Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. <i>Journal of Nuclear Medicine</i> , <b>2001</b> , 42, 1591-5	8.9	133
508	King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation. <i>Movement Disorders</i> , <b>2015</b> , 30, 1623-31	7	131
507	Adherence to antiparkinson medication in a multicenter European study. <i>Movement Disorders</i> , <b>2009</b> , 24, 826-32	7	131
506	Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. <i>Movement Disorders</i> , <b>2017</b> , 32, 955-971	7	127
505	Dopamine transporter imaging with fluorine-18-FPCIT and PET. <i>Journal of Nuclear Medicine</i> , <b>1998</b> , 39, 1521-30	8.9	125
504	<sup>123</sup> I-loflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. <i>Neurological Sciences</i> , <b>2003</b> , 24, 149-50	3.5	122
503	Outcome of Parkinson's Disease Patients Affected by COVID-19. <i>Movement Disorders</i> , <b>2020</b> , 35, 905-908	7	120
502	Identification of circulating microRNAs for the differential diagnosis of Parkinson's disease and Multiple System Atrophy. <i>Frontiers in Cellular Neuroscience</i> , <b>2014</b> , 8, 156	6.1	119
501	The relationship between impulsivity and impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , <b>2008</b> , 23, 411-5	7	119
500	Tuning AlAs-GaAs band discontinuities and the role of Si-induced local interface dipoles. <i>Physical Review B</i> , <b>1991</b> , 43, 2450-2453	3.3	118

499	Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling. <i>Neurobiology of Disease</i> , <b>2010</b> , 39, 98-104	7.5	117
498	Impulsivity and compulsivity in drug-naïve patients with Parkinson's disease. <i>Movement Disorders</i> , <b>2011</b> , 26, 464-8	7	115
497	Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. <i>Journal of Neurology</i> , <b>2010</b> , 257, 5-14	5.5	115
496	Ultrastructural evidence for synaptic interactions between thalamocortical axons and subplate neurons. <i>European Journal of Neuroscience</i> , <b>1994</b> , 6, 1729-42	3.5	115
495	Mesiotemporal versus lateral temporal lobe epilepsy: metabolic differences in the temporal lobe shown by interictal 18F-FDG positron emission tomography. <i>Neurology</i> , <b>1993</b> , 43, 79-86	6.5	115
494	Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. <i>Parkinsonism and Related Disorders</i> , <b>2015</b> , 21, 1133-44	3.6	113
493	Cerebral glucose metabolism in women with panic disorder. <i>American Journal of Psychiatry</i> , <b>1998</b> , 155, 1178-83	11.9	112
492	Functional abnormalities underlying pathological gambling in Parkinson disease. <i>Archives of Neurology</i> , <b>2008</b> , 65, 1604-11		109
491	Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: a PET study of resting-state glucose metabolism. <i>Brain</i> , <b>2001</b> , 124, 1601-9	11.2	109
490	Plasticity of geniculocortical afferents following brief or prolonged monocular occlusion in the cat. <i>Journal of Comparative Neurology</i> , <b>1996</b> , 369, 64-82	3.4	109
489	[11C]raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length. <i>Annals of Neurology</i> , <b>1998</b> , 43, 253-5	9.4	107
488	Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2006</b> , 77, 450-3	5.5	103
487	Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. <i>Journal of Neurology</i> , <b>2013</b> , 260, 2701-14	5.5	102
486	Metabolic correlates of pallidal neuronal activity in Parkinson's disease. <i>Brain</i> , <b>1997</b> , 120 ( Pt 8), 1315-24	11.2	100
485	Relation Between Putative Transmitter Phenotypes and Connectivity of Subplate Neurons During Cerebral Cortical Development. <i>European Journal of Neuroscience</i> , <b>1990</b> , 2, 744-761	3.5	100
484	Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. <i>Parkinsonism and Related Disorders</i> , <b>2015</b> , 21, 231-5	3.6	99
483	Emergence of ocular dominance columns in cat visual cortex by 2 weeks of age. <i>Journal of Comparative Neurology</i> , <b>2001</b> , 430, 235-49	3.4	98
482	Regulation of ER-mitochondria contacts by Parkin via Mfn2. <i>Pharmacological Research</i> , <b>2018</b> , 138, 43-56	10.2	97

481	Functional correlates of pallidal stimulation for Parkinson's disease. <i>Annals of Neurology</i> , <b>2001</b> , 49, 155-64	9.4	96
480	Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER. <i>Parkinsonism and Related Disorders</i> , <b>2013</b> , 19, 660-5	3.6	94
479	A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. <i>Journal of Neurology</i> , <b>2011</b> , 258, 579-85	5.5	94
478	Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. <i>Parkinsonism and Related Disorders</i> , <b>2017</b> , 45, 13-20	3.6	93
477	Pathological gambling in patients with Parkinson's disease is associated with fronto-striatal disconnection: a path modeling analysis. <i>Movement Disorders</i> , <b>2011</b> , 26, 225-33	7	93
476	Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET. <i>Movement Disorders</i> , <b>1998</b> , 13, 268-74	7	92
475	The metabolic anatomy of tremor in Parkinson's disease. <i>Neurology</i> , <b>1998</b> , 51, 803-10	6.5	91
474	Early DEtection of wEaring off in Parkinson disease: the DEEP study. <i>Parkinsonism and Related Disorders</i> , <b>2014</b> , 20, 204-11	3.6	90
473	Reproducibility of regional metabolic covariance patterns: comparison of four populations. <i>Journal of Nuclear Medicine</i> , <b>1999</b> , 40, 1264-9	8.9	90
472	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. <i>Movement Disorders</i> , <b>2017</b> , 32, 995-1005	7	88
471	Wearable sensor-based objective assessment of motor symptoms in Parkinson's disease. <i>Journal of Neural Transmission</i> , <b>2016</b> , 123, 57-64	4.3	87
470	Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life. <i>Movement Disorders</i> , <b>2006</b> , 21, 1119-22	7	86
469	Tolerability of paroxetine in Parkinson's disease: a prospective study. <i>Movement Disorders</i> , <b>2000</b> , 15, 986-9	7	86
468	Validation of the Italian version of the Movement Disorder Society--Unified Parkinson's Disease Rating Scale. <i>Neurological Sciences</i> , <b>2013</b> , 34, 683-7	3.5	85
467	LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample. <i>Parkinsonism and Related Disorders</i> , <b>2006</b> , 12, 410-9	3.6	85
466	Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect. <i>Journal of Parkinson's Disease</i> , <b>2011</b> , 1, 197-203	5.3	83
465	Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease. <i>Neurodegenerative Diseases</i> , <b>2008</b> , 5, 244-6	2.3	83
464	ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2017</b> , 88, 317-324	5.5	82

463	Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach. <i>Current Medical Research and Opinion</i> , <b>2018</b> , 34, 2063-2073	2.5	82
462	Dynamic functional connectivity changes associated with dementia in Parkinson's disease. <i>Brain</i> , <b>2019</b> , 142, 2860-2872	11.2	81
461	EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease. <i>Movement Disorders</i> , <b>2019</b> , 34, 353-365	7	80
460	MR imaging of the superior profile of the midbrain: differential diagnosis between progressive supranuclear palsy and Parkinson disease. <i>American Journal of Neuroradiology</i> , <b>2004</b> , 25, 927-32	4.4	79
459	Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery. <i>Parkinsonism and Related Disorders</i> , <b>2013</b> , 19, 501-7 ; discussion 501	3.6	77
458	Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism. <i>Movement Disorders</i> , <b>2002</b> , 17, 1265-70	7	77
457	Medical and surgical management of advanced Parkinson's disease. <i>Movement Disorders</i> , <b>2018</b> , 33, 900-908		76
456	MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study. <i>Journal of Neural Transmission</i> , <b>2016</b> , 123, 431-8	4.3	76
455	The status of dopamine nerve terminals in Parkinson's disease and essential tremor: a PET study with the tracer [11-C]FE-CIT. <i>Neurological Sciences</i> , <b>2001</b> , 22, 47-8	3.5	74
454	A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need. <i>PLoS ONE</i> , <b>2013</b> , 8, e57221	3.7	73
453	Dopamine Transporter SPECT Imaging in Corticobasal Syndrome. <i>PLoS ONE</i> , <b>2011</b> , 6, e18301	3.7	73
452	Excessive daytime sleepiness in multiple system atrophy (SLEEMSA study). <i>Archives of Neurology</i> , <b>2011</b> , 68, 223-30		73
451	Doped LiMn Spinels: Physical/Chemical Characteristics and Electrochemical Performance in Li Batteries. <i>Chemistry of Materials</i> , <b>1997</b> , 9, 1443-1450	9.6	73
450	Radiosynthesis of [18F] N-3-fluoropropyl-2-beta-carbomethoxy-3-beta-(4-iodophenyl) nortropane and the first human study with positron emission tomography. <i>Nuclear Medicine and Biology</i> , <b>1996</b> , 23, 999-1004	2.1	73
449	The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: a simple grading system. <i>Parkinsonism and Related Disorders</i> , <b>2015</b> , 21, 287-91	3.6	72
448	Beneficial Effects of Bilateral Subthalamic Stimulation on Non-Motor Symptoms in Parkinson's Disease. <i>Brain Stimulation</i> , <b>2016</b> , 9, 78-85	5.1	71
447	Management of impulse control disorders in Parkinson's disease: Controversies and future approaches. <i>Movement Disorders</i> , <b>2015</b> , 30, 150-9	7	71
446	Wearing-off scales in Parkinson's disease: critique and recommendations. <i>Movement Disorders</i> , <b>2011</b> , 26, 2169-75	7	68

445	Pioneer neurons and target selection in cerebral cortical development. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , <b>1990</b> , 55, 469-80	3.9	68
444	Surgical, medical, and hardware adverse events in a series of 141 patients undergoing subthalamic deep brain stimulation for Parkinson disease. <i>World Neurosurgery</i> , <b>2010</b> , 73, 338-44	2.1	67
443	Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and prevention. <i>Drug Safety</i> , <b>2009</b> , 32, 475-88	5.1	66
442	COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside. <i>Npj Parkinson's Disease</i> , <b>2020</b> , 6, 18	9.7	66
441	The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward. <i>Movement Disorders</i> , <b>2017</b> , 32, 510-525	7	65
440	Cognitive decline in Parkinson's disease: the complex picture. <i>Npj Parkinson's Disease</i> , <b>2016</b> , 2, 16018	9.7	65
439	Cerebral glucose metabolism in patients with spasmodic torticollis. <i>Movement Disorders</i> , <b>1997</b> , 12, 704-87		65
438	Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2012</b> , 83, 76-82	5.5	64
437	Imaging essential tremor. <i>Movement Disorders</i> , <b>2010</b> , 25, 679-86	7	64
436	Clinical correlates and cognitive underpinnings of verbal fluency impairment after chronic subthalamic stimulation in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2006</b> , 12, 289-95	3.6	64
435	Dopamine D2 receptors in normal human brain: effect of age measured by positron emission tomography (PET) and [ <sup>11</sup> C]-raclopride. <i>Annals of the New York Academy of Sciences</i> , <b>1993</b> , 695, 81-5	6.5	64
434	Patterns of cortical thickness associated with impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , <b>2015</b> , 30, 688-95	7	63
433	Cognitive profiling of Parkinson disease patients with mild cognitive impairment and dementia. <i>Parkinsonism and Related Disorders</i> , <b>2014</b> , 20, 394-9	3.6	62
432	Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management. <i>Expert Review of Neurotherapeutics</i> , <b>2009</b> , 9, 859-67	4.3	62
431	Preoperative and postoperative glucose consumption in mesiobasal and lateral temporal lobe epilepsy. <i>Neurology</i> , <b>1994</b> , 44, 2125-32	6.5	61
430	Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients. <i>Movement Disorders</i> , <b>2016</b> , 31, 530-7	7	61
429	A cross-sectional multicenter study of cognitive and behavioural features in multiple system atrophy patients of the parkinsonian and cerebellar type. <i>Journal of Neural Transmission</i> , <b>2013</b> , 120, 613-8	4.3	60
428	Striatal dopamine transporter abnormalities in patients with essential tremor. <i>Nuclear Medicine Communications</i> , <b>2008</b> , 29, 349-53	1.6	59



427	Prevalence and associated features of self-reported freezing of gait in Parkinson disease: The DEEP FOG study. <i>Parkinsonism and Related Disorders</i> , <b>2015</b> , 21, 644-9	3.6	58
426	Novel formulations and modes of delivery of levodopa. <i>Movement Disorders</i> , <b>2015</b> , 30, 114-20	7	58
425	PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum. <i>Human Mutation</i> , <b>2008</b> , 29, 565	4.7	58
424	Hydrocarbon exposure and Parkinson's disease. <i>Neurology</i> , <b>2000</b> , 55, 667-73	6.5	58
423	A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists. <i>European Journal of Neurology</i> , <b>2016</b> , 23, 1255-61	6	58
422	A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients. <i>European Journal of Neurology</i> , <b>2015</b> , 22, 1184-91	6	57
421	Brain volume changes in Parkinson's disease and their relationship with cognitive and behavioural abnormalities. <i>Journal of the Neurological Sciences</i> , <b>2011</b> , 310, 64-9	3.2	57
420	How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. <i>Parkinsonism and Related Disorders</i> , <b>2007</b> , 13, 528-31	3.6	57
419	Morphology of single geniculocortical afferents and functional recovery of the visual cortex after reverse monocular deprivation in the kitten. <i>Journal of Neuroscience</i> , <b>1998</b> , 18, 9896-909	6.6	57
418	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , <b>2019</b> , 34, 1228-1232	7	56
417	Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens. <i>Parkinsonism and Related Disorders</i> , <b>2014</b> , 20, 27-31	3.6	56
416	Perfusion ECD/SPECT in the characterization of cognitive deficits in Parkinson's disease. <i>Neurological Sciences</i> , <b>2001</b> , 22, 45-6	3.5	56
415	Benzodiazepine receptor binding in Huntington's disease: [11C]Flumazenil uptake measured using positron emission tomography. <i>Annals of Neurology</i> , <b>2000</b> , 47, 644-648	9.4	56
414	Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. <i>Journal of Neurology</i> , <b>2009</b> , 256, 910-5	5.5	55
413	Preoperative indicators of clinical outcome following stereotaxic pallidotomy. <i>Neurology</i> , <b>1997</b> , 49, 1083-90	6.9	55
412	Management of Advanced Therapies in Parkinson's Disease Patients in Times of Humanitarian Crisis: The COVID-19 Experience. <i>Movement Disorders Clinical Practice</i> , <b>2020</b> , 7, 361-372	2.2	55
411	Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease. <i>NeuroImage: Clinical</i> , <b>2017</b> , 14, 734-740	5.3	54
410	Non-motor outcomes depend on location of neurostimulation in Parkinson's disease. <i>Brain</i> , <b>2019</b> , 142, 3592-3604	11.2	54

409	Nonmotor symptoms evolution during 24 months of bilateral subthalamic stimulation in Parkinson's disease. <i>Movement Disorders</i> , <b>2018</b> , 33, 421-430	7	52
408	Cognitive and MRI correlates of orthostatic hypotension in Parkinson's disease. <i>Journal of Neurology</i> , <b>2013</b> , 260, 253-9	5.5	52
407	Default mode network links to visual hallucinations: A comparison between Parkinson's disease and multiple system atrophy. <i>Movement Disorders</i> , <b>2015</b> , 30, 1237-47	7	52
406	Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial. <i>European Journal of Neurology</i> , <b>2015</b> , 22, 1400-7	6	52
405	Role of genetic polymorphisms of the dopaminergic system in Parkinson's disease patients with impulse control disorders. <i>Parkinsonism and Related Disorders</i> , <b>2012</b> , 18, 397-9	3.6	52
404	Effect and safety of duodenal levodopa infusion in advanced Parkinson's disease: a retrospective multicenter outcome assessment in patient routine care. <i>Journal of Neural Transmission</i> , <b>2013</b> , 120, 1553-8	4.3	51
403	Whole gene deletion and splicing mutations expand the PINK1 genotypic spectrum. <i>Human Mutation</i> , <b>2007</b> , 28, 98	4.7	51
402	Novel parkin mutations detected in patients with early-onset Parkinson's disease. <i>Movement Disorders</i> , <b>2005</b> , 20, 424-431	7	51
401	First results from the high energy resolution photoemission beam line at ELETTRA. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , <b>1995</b> , 364, 374-379	1.2	51
400	Impulse control disorders in advanced Parkinson's disease with dyskinesia: The ALTHEA study. <i>Movement Disorders</i> , <b>2017</b> , 32, 1557-1565	7	50
399	Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2009</b> , 15 Suppl 4, S97-100	3.6	50
398	Brain networks underlining verbal fluency decline during STN-DBS in Parkinson's disease: an ECD-SPECT study. <i>Parkinsonism and Related Disorders</i> , <b>2007</b> , 13, 290-4	3.6	50
397	Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson's disease. <i>Npj Parkinson's Disease</i> , <b>2018</b> , 4, 14	9.7	49
396	Grey matter changes in cognitively impaired Parkinson's disease patients. <i>PLoS ONE</i> , <b>2014</b> , 9, e85595	3.7	49
395	The relationship between cerebral vascular disease and parkinsonism: The VADO study. <i>Parkinsonism and Related Disorders</i> , <b>2012</b> , 18, 775-80	3.6	49
394	Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease. <i>CNS Drugs</i> , <b>2010</b> , 24, 119-29	6.7	49
393	Intrajejunal levodopa versus conventional therapy in Parkinson disease: motor and nonmotor effects. <i>Clinical Neuropharmacology</i> , <b>2012</b> , 35, 205-7	1.4	48
392	[123I]FP-CIT striatal binding in early Parkinson's disease patients with tremor vs. akinetic-rigid onset. <i>NeuroReport</i> , <b>2007</b> , 18, 1499-502	1.7	48

391	Physiological organization of callosal connections of a visual lateral suprasylvian cortical area in the cat. <i>Journal of Neurophysiology</i> , <b>1983</b> , 49, 902-21	3.2	48
390	COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features. <i>Neuropsychiatric Disease and Treatment</i> , <b>2008</b> , 4, 1-9	3.1	47
389	An overnight switch to ropinirole therapy in patients with Parkinson's disease. Short communication. <i>Journal of Neural Transmission</i> , <b>1999</b> , 106, 925-9	4.3	47
388	Pain in Parkinson's disease: facts and uncertainties. <i>European Journal of Neurology</i> , <b>2018</b> , 25, 917-e69	6	46
387	Characterizing motor and non-motor aspects of early-morning off periods in Parkinson's disease: an international multicenter study. <i>Parkinsonism and Related Disorders</i> , <b>2014</b> , 20, 1231-5	3.6	46
386	Magnetic Resonance Parkinsonism Index: diagnostic accuracy of a fully automated algorithm in comparison with the manual measurement in a large Italian multicentre study in patients with progressive supranuclear palsy. <i>European Radiology</i> , <b>2017</b> , 27, 2665-2675	8	46
385	Anatomical and functional correlates of persistent pain in Parkinson's disease. <i>Movement Disorders</i> , <b>2016</b> , 31, 1854-1864	7	46
384	Double-blind Randomized Trial of tDCS Versus Sham in Parkinson Patients With Mild Cognitive Impairment Receiving Cognitive Training. <i>Brain Stimulation</i> , <b>2015</b> , 8, 1223-5	5.1	45
383	Peripheral nervous system involvement in Parkinson's disease: evidence and controversies. <i>Parkinsonism and Related Disorders</i> , <b>2014</b> , 20, 1329-34	3.6	45
382	USP14 inhibition corrects an model of impaired mitophagy. <i>EMBO Molecular Medicine</i> , <b>2018</b> , 10,	12	45
381	A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , <b>2019</b> , 34, 975-984	7	44
380	Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease. <i>Expert Opinion on Drug Safety</i> , <b>2015</b> , 14, 281-94	4.1	44
379	Do patients with late-stage Parkinson's disease still respond to levodopa?. <i>Parkinsonism and Related Disorders</i> , <b>2016</b> , 26, 10-6	3.6	44
378	Loss of thalamic serotonin transporters in early drug-naïve Parkinson's disease patients is associated with tremor: an [(123)I]beta-CIT SPECT study. <i>Journal of Neural Transmission</i> , <b>2008</b> , 115, 721-4.3	4.3	44
377	Importance of corpus callosum for visual receptive fields of single neurons in cat superior colliculus. <i>Journal of Neurophysiology</i> , <b>1979</b> , 42, 137-52	3.2	44
376	Factors Affecting the Stabilization of Mn Spinel Capacity upon Staring and Cycling at High Temperatures. <i>Journal of the Electrochemical Society</i> , <b>1998</b> , 145, 2726-2732	3.9	43
375	Increased cerebral iron uptake in Wilson's disease: a <sup>52</sup> Fe-citrate PET study. <i>Journal of Nuclear Medicine</i> , <b>2000</b> , 41, 781-7	8.9	43
374	Anatomical correlates of cognitive functions in early Parkinson's disease patients. <i>PLoS ONE</i> , <b>2013</b> , 8, e64222	3.7	42

373	Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia. <i>Movement Disorders</i> , <b>2009</b> , 24, 1028-33	7	42
372	Cognitive status of patients with Parkinson's disease and pathological gambling. <i>Journal of Neurology</i> , <b>2010</b> , 257, 247-52	5.5	42
371	Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years. <i>Archives of Gerontology and Geriatrics</i> , <b>2004</b> , 291-6	4	42
370	Brain SPECT imaging in multiple system atrophy. <i>Journal of Neural Transmission</i> , <b>2005</b> , 112, 1635-45	4.3	42
369	Structure and local dipole of Si interface layers in AlAs-GaAs heterostructures. <i>Physical Review B</i> , <b>1992</b> , 46, 6834-6845	3.3	42
368	Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis. <i>European Journal of Neurology</i> , <b>2016</b> , 23, 1556-65	6	42
367	[123I]FP-CIT SPET imaging in drug-induced Parkinsonism. <i>Movement Disorders</i> , <b>2008</b> , 23, 1825-9	7	41
366	Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy. <i>Movement Disorders</i> , <b>2008</b> , 23, 2202-9	7	41
365	Thin section MR study of the basal ganglia in the differential diagnosis between striatonigral degeneration and Parkinson disease. <i>Journal of Computer Assisted Tomography</i> , <b>2002</b> , 26, 266-71	2.2	41
364	n-Hexane-induced parkinsonism: pathogenetic hypotheses. <i>Movement Disorders</i> , <b>1995</b> , 10, 279-82	7	41
363	AlAs-GaAs heterojunction engineering by means of group-IV elemental interface layers. <i>Physical Review B</i> , <b>1992</b> , 45, 4528-4531	3.3	41
362	Extradural motor cortex stimulation in Parkinson's disease. <i>Movement Disorders</i> , <b>2007</b> , 22, 111-4	7	40
361	Role of pramipexole in the management of Parkinson's disease. <i>CNS Drugs</i> , <b>2010</b> , 24, 829-41	6.7	39
360	Anhedonia and cognitive impairment in Parkinson's disease: Italian validation of the Snaith-Hamilton Pleasure Scale and its application in the clinical routine practice during the PRIAMO study. <i>Parkinsonism and Related Disorders</i> , <b>2009</b> , 15, 576-81	3.6	39
359	Dopa-responsive pseudo-orthostatic tremor in parkinsonism. <i>Movement Disorders</i> , <b>2007</b> , 22, 1652-6	7	39
358	Pisa syndrome without neuroleptic exposure in a patient with Parkinson's disease: case report. <i>Movement Disorders</i> , <b>2006</b> , 21, 270-3	7	39
357	Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy. <i>Journal of Neural Transmission</i> , <b>2016</b> , 123, 1435-1442	4.3	39
356	Stridor in multiple system atrophy: Consensus statement on diagnosis, prognosis, and treatment. <i>Neurology</i> , <b>2019</b> , 93, 630-639	6.5	38

355	The "gender factor" in wearing-off among patients with Parkinson's disease: a post hoc analysis of DEEP study. <i>Scientific World Journal, The</i> , <b>2015</b> , 2015, 787451	2.2	38
354	Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation. <i>Movement Disorders</i> , <b>2007</b> , 22, 275-8	7	38
353	Photoemission from atomic and molecular adsorbates on Rh(100). <i>Surface Science</i> , <b>1996</b> , 347, 53-62	1.8	38
352	PD_Manager: an mHealth platform for Parkinson's disease patient management. <i>Healthcare Technology Letters</i> , <b>2017</b> , 4, 102-108	1.9	37
351	Parkin analysis in early onset Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2008</b> , 14, 326-33	3.6	37
350	Wild-type p53 gene transfer inhibits invasion and reduces matrix metalloproteinase-2 levels in p53-mutated human melanoma cells. <i>Journal of Investigative Dermatology</i> , <b>2000</b> , 114, 1188-94	4.3	37
349	Epilepsia partialis continua studied by PET. <i>Epilepsy Research</i> , <b>1991</b> , 9, 44-8	3	37
348	Targeting of the Subthalamic Nucleus for Deep Brain Stimulation: A Survey Among Parkinson Disease Specialists. <i>World Neurosurgery</i> , <b>2017</b> , 99, 41-46	2.1	36
347	Brain structural profile of multiple system atrophy patients with cognitive impairment. <i>Journal of Neural Transmission</i> , <b>2017</b> , 124, 293-302	4.3	36
346	Clinical and cerebral activity changes induced by subthalamic nucleus stimulation in advanced Parkinson's disease: a prospective case-control study. <i>Clinical Neurology and Neurosurgery</i> , <b>2009</b> , 111, 140-6	2	36
345	Comparative analysis of visual and semi-quantitative assessment of striatal [123I]FP-CIT-SPET binding in Parkinson's disease. <i>Neurological Sciences</i> , <b>2006</b> , 27, 397-401	3.5	36
344	Callosum-dependent binocular interactions in the lateral suprasylvian area of Siamese cats which lack binocular neurons in areas 17 and 18. <i>Brain Research</i> , <b>1980</b> , 197, 230-5	3.7	36
343	Indirect, across-the-midline retinotectal projections and representation of ipsilateral visual field in superior colliculus of the cat. <i>Journal of Neurophysiology</i> , <b>1978</b> , 41, 285-304	3.2	36
342	A signature pattern of cortical atrophy in dementia with Lewy bodies: A study on 333 patients from the European DLB consortium. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 400-409	1.2	36
341	Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. <i>Parkinsonism and Related Disorders</i> , <b>2017</b> , 38, 90-92	3.6	35
340	Diagnostic and screening power of neuropsychological testing in detecting mild cognitive impairment in Parkinson's disease. <i>Journal of Neural Transmission</i> , <b>2013</b> , 120, 627-33	4.3	35
339	The status of olfactory function and the striatal dopaminergic system in drug-induced parkinsonism. <i>Journal of Neurology</i> , <b>2010</b> , 257, 1882-9	5.5	35
338	Temporal lobe epilepsy: correlation of proton magnetic resonance spectroscopy and 18F-fluorodeoxyglucose positron emission tomography. <i>Magnetic Resonance in Medicine</i> , <b>1997</b> , 37, 18-23	4.4	35

337	Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation. <i>Movement Disorders</i> , <b>2006</b> , 21, 1144-7	7	35
336	Comparison of 123I-IBZM SPECT and 11C-raclopride PET findings in patients with parkinsonism. <i>Nuclear Medicine Communications</i> , <b>1994</b> , 15, 806-13	1.6	35
335	The contribution of the corpus callosum to receptive fields in the lateral suprasylvian visual areas of the cat. <i>Behavioural Brain Research</i> , <b>1982</b> , 4, 155-76	3.4	35
334	The contribution of white matter lesions to Parkinson's disease motor and gait symptoms: a critical review of the literature. <i>Journal of Neural Transmission</i> , <b>2016</b> , 123, 241-50	4.3	34
333	The effect of doping LiMn2O4 spinel on its use as a cathode in Li-ion batteries: neutron diffraction and electrochemical studies. <i>Journal of Physics and Chemistry of Solids</i> , <b>2004</b> , 65, 29-37	3.9	34
332	Tailoring of silicon crystals for relativistic-particle channeling. <i>Nuclear Instruments &amp; Methods in Physics Research B</i> , <b>2005</b> , 234, 40-46	1.2	34
331	Increased striatal glucose consumption in Sydenham's chorea. <i>Movement Disorders</i> , <b>1993</b> , 8, 437-44	7	34
330	Nutritional habits, risk, and progression of Parkinson disease. <i>Journal of Neurology</i> , <b>2018</b> , 265, 12-23	5.5	33
329	Disease progression in Parkinson subtypes: the PPMI dataset. <i>Neurological Sciences</i> , <b>2018</b> , 39, 1971-1976	3.5	33
328	Psychiatric symptoms in Parkinson's disease assessed with the SCL-90R self-reported questionnaire. <i>Neurological Sciences</i> , <b>2010</b> , 31, 35-40	3.5	33
327	Anatomical identification of active contacts in subthalamic deep brain stimulation. <i>World Neurosurgery</i> , <b>2007</b> , 67, 140-6; discussion 146-7		33
326	Pramipexole-treated Parkinson's disease during pregnancy. <i>Movement Disorders</i> , <b>2004</b> , 19, 1114-5	7	33
325	Visual and somatosensory integration in the anterior ectosylvian cortex of the cat. <i>Brain Research</i> , <b>1987</b> , 410, 21-31	3.7	33
324	Binocularity in the visual cortex of the adult cat does not depend on the integrity of the corpus callosum. <i>Behavioural Brain Research</i> , <b>1984</b> , 13, 183-92	3.4	33
323	Multilayer SiC for thermal protection system of space vehicles with decreased thermal conductivity through the thickness. <i>Journal of the European Ceramic Society</i> , <b>2010</b> , 30, 1833-1840	6	32
322	Continuous dopaminergic stimulation--from theory to clinical practice. <i>Parkinsonism and Related Disorders</i> , <b>2007</b> , 13 Suppl, S24-8	3.6	32
321	Autosomal recessive early onset parkinsonism is linked to three loci: PARK2, PARK6, and PARK7. <i>Neurological Sciences</i> , <b>2002</b> , 23 Suppl 2, S59-60	3.5	32
320	Quality of life outcome after subthalamic stimulation in Parkinson's disease depends on age. <i>Movement Disorders</i> , <b>2018</b> , 33, 99-107	7	32

319	Caregiver burden and its related factors in advanced Parkinson's disease: data from the PREDICT study. <i>Journal of Neurology</i> , <b>2018</b> , 265, 1124-1137	5.5	31
318	Buckwheat achenes antioxidant profile modulates <i>Aspergillus flavus</i> growth and aflatoxin production. <i>International Journal of Food Microbiology</i> , <b>2014</b> , 189, 1-10	5.8	31
317	A Consensus Set of Outcomes for Parkinson's Disease from the International Consortium for Health Outcomes Measurement. <i>Journal of Parkinson's Disease</i> , <b>2017</b> , 7, 533-543	5.3	31
316	Speech and Voice Response to a Levodopa Challenge in Late-Stage Parkinson's Disease. <i>Frontiers in Neurology</i> , <b>2017</b> , 8, 432	4.1	31
315	Predictive value of nigrostriatal dysfunction in isolated tremor: a clinical and SPECT study. <i>Movement Disorders</i> , <b>2008</b> , 23, 2049-54	7	31
314	Dopamine transporter imaging study in parkinsonism occurring in fragile X premutation carriers. <i>Neurology</i> , <b>2005</b> , 65, 1971-3	6.5	31
313	Effect of sensory disuse on geniculate afferents to cat visual cortex. <i>Visual Neuroscience</i> , <b>1998</b> , 15, 401-9	1.7	31
312	Should there be less emphasis on levodopa-induced dyskinesia in Parkinson's disease?. <i>Movement Disorders</i> , <b>2019</b> , 34, 816-819	7	30
311	alpha-Synuclein multiplication analysis in Italian familial Parkinson disease. <i>Parkinsonism and Related Disorders</i> , <b>2010</b> , 16, 228-31	3.6	30
310	Increased oxidative stress in lymphocytes from untreated Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , <b>2009</b> , 15, 327-8	3.6	30
309	Biological effects of the PINK1 c.1366C>T mutation: implications in Parkinson disease pathogenesis. <i>Neurogenetics</i> , <b>2007</b> , 8, 103-9	3	30
308	PET and SPECT functional imaging in Parkinson's disease. <i>Sleep Medicine</i> , <b>2004</b> , 5, 201-6	4.6	30
307	Epitaxial growth and interface parameters of Si layers on GaAs(001) and AlAs(001) substrates. <i>Journal of Vacuum Science &amp; Technology an Official Journal of the American Vacuum Society B, Microelectronics Processing and Phenomena</i> , <b>1991</b> , 9, 2225		30
306	The PRIAMO study: urinary dysfunction as a marker of disease progression in early Parkinson's disease. <i>European Journal of Neurology</i> , <b>2017</b> , 24, 788-795	6	29
305	Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test. <i>Parkinsonism and Related Disorders</i> , <b>2017</b> , 39, 37-43	3.6	29
304	Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , <b>2017</b> , 7, 491-501	5.3	29
303	Spinal cord stimulation for the treatment of sensory symptoms in advanced Parkinson's disease. <i>Neuromodulation</i> , <b>2013</b> , 16, 276-9	3.1	29
302	The efficacy of oral adenosine A(2A) antagonist istradefylline for the treatment of moderate to severe Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , <b>2015</b> , 15, 1383-90	4.3	29

301	Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease. <i>Neurological Sciences</i> , <b>2003</b> , 24, 174-5	3.5	29
300	A morphological study of SEI film on graphite electrodes. <i>Journal of Power Sources</i> , <b>2001</b> , 97-98, 146-150	9	29
299	Learning and interhemispheric transfer of visual pattern discriminations following unilateral suprasylvian lesions in split-chiasm cats. <i>Experimental Brain Research</i> , <b>1979</b> , 34, 551-74	2.3	29
298	Parkinson's Disease and Post-COVID-19 Syndrome: The Parkinson's Long-COVID Spectrum. <i>Movement Disorders</i> , <b>2021</b> , 36, 1287-1289	7	29
297	Switching from constant voltage to constant current in deep brain stimulation: a multicenter experience of mixed implants for movement disorders. <i>European Journal of Neurology</i> , <b>2016</b> , 23, 190-5	6	29
296	Short-term quality of life after subthalamic stimulation depends on non-motor symptoms in Parkinson's disease. <i>Brain Stimulation</i> , <b>2018</b> , 11, 867-874	5.1	28
295	Non-motor outcomes of subthalamic stimulation in Parkinson's disease depend on location of active contacts. <i>Brain Stimulation</i> , <b>2018</b> , 11, 904-912	5.1	28
294	Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection. <i>Functional Neurology</i> , <b>2012</b> , 27, 147-54	2.2	28
293	Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study. <i>Journal of Neurology</i> , <b>2019</b> , 266, 2164-2176	5.5	27
292	Reasons for hospitalization in Parkinson's disease: a case-control study. <i>Parkinsonism and Related Disorders</i> , <b>2014</b> , 20, 488-92; discussion 488	3.6	27
291	Differential neuropsychological profiles in Parkinsonian patients with or without vascular lesions. <i>Movement Disorders</i> , <b>2010</b> , 25, 50-6	7	27
290	D2 receptor binding in dopa-responsive dystonia. <i>Annals of Neurology</i> , <b>1998</b> , 44, 758-62	9.4	27
289	Cognitive Rehabilitation in Parkinson's Disease: Is it Feasible?. <i>Archives of Clinical Neuropsychology</i> , <b>2017</b> , 32, 840-860	2.7	26
288	The reliability of a deep learning model in clinical out-of-distribution MRI data: A multicohort study. <i>Medical Image Analysis</i> , <b>2020</b> , 66, 101714	15.4	26
287	Evidence of delayed nigrostriatal dysfunction in corticobasal syndrome: a SPECT follow-up study. <i>Parkinsonism and Related Disorders</i> , <b>2013</b> , 19, 557-9	3.6	26
286	Deep brain stimulation and its effect on sleep in Parkinson's disease. <i>Sleep Medicine</i> , <b>2004</b> , 5, 211-4	4.6	26
285	Impedance study on the reactivity of gel polymer electrolytes towards a lithium electrode. <i>Journal of Power Sources</i> , <b>1996</b> , 58, 139-144	8.9	26
284	Interhemispheric influences on area 19 of the cat. <i>Experimental Brain Research</i> , <b>1985</b> , 59, 171-84	2.3	26



283	Water-based vs. non-water-based physiotherapy for rehabilitation of postural deformities in Parkinson's disease: a randomized controlled pilot study. <i>Clinical Rehabilitation</i> , <b>2017</b> , 31, 1107-1115	3.3	25
282	Secondary parkinsonism due to focal substantia nigra lesions: a PET study with [18F]FDG and [18F]fluorodopa. <i>Acta Neurologica Scandinavica</i> , <b>1996</b> , 93, 387-92	3.8	25
281	Dopamine agonist-based strategies in the treatment of Parkinson's disease. <i>Neurological Sciences</i> , <b>2008</b> , 29 Suppl 5, S371-4	3.5	25
280	Genetic, clinical, and imaging characterization of one patient with late-onset, slowly progressive, pantothenate kinase-associated neurodegeneration. <i>Movement Disorders</i> , <b>2006</b> , 21, 417-8	7	25
279	Band offsets and strain in CdTe-GaAs heterostructures. <i>Physical Review B</i> , <b>1993</b> , 48, 8899-8910	3.3	25
278	Uptake of radiocesium by mushrooms. <i>Science of the Total Environment</i> , <b>1991</b> , 106, 183-90	10.2	25
277	A voxel-based PET study of dopamine transporters in Parkinson's disease: relevance of age at onset. <i>Neurobiology of Disease</i> , <b>2008</b> , 31, 102-9	7.5	24
276	The PRIAMO study: background, methods and recruitment. <i>Neurological Sciences</i> , <b>2008</b> , 29, 61-5	3.5	24
275	Striatal dopamine D2 receptors in patients with narcolepsy measured with PET and 11C-raclopride. <i>Neurology</i> , <b>1994</b> , 44, 2102-4	6.5	24
274	Diagnosing dementia in multiple system atrophy by applying Movement Disorder Society diagnostic criteria for Parkinson's disease dementia. <i>Parkinsonism and Related Disorders</i> , <b>2015</b> , 21, 1273-7	3.6	23
273	Synthesis of Mn spinels from different polymorphs of MnO <sub>2</sub> . <i>Journal of Power Sources</i> , <b>1995</b> , 56, 37-43	8.9	23
272	Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies. <i>Movement Disorders</i> , <b>2020</b> , 35, 171-176	7	23
271	Distribution and impact on quality of life of the pain modalities assessed by the King's Parkinson's disease pain scale. <i>Npj Parkinson's Disease</i> , <b>2017</b> , 3, 8	9.7	22
270	Cerebral autoregulation and white matter lesions in Parkinson's disease and multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , <b>2015</b> , 21, 1393-7	3.6	22
269	Diagnosis of possible mild cognitive impairment in Parkinson's disease: validity of the SCOPA-Cog. <i>Parkinsonism and Related Disorders</i> , <b>2013</b> , 19, 1160-3	3.6	22
268	Effect of partial Ga <sup>3+</sup> substitution for Mn <sup>3+</sup> in LiMn <sub>2</sub> O <sub>4</sub> on its behaviour as a cathode for Li cells. <i>Journal of Electroanalytical Chemistry</i> , <b>1996</b> , 410, 115-118	4.1	22
267	Mapping subcortical extrarelay afferents onto primary somatosensory and visual areas in cats. <i>Journal of Comparative Neurology</i> , <b>1995</b> , 362, 46-70	3.4	22
266	Treatment with D-penicillamine improves dopamine D2-receptor binding and T2-signal intensity in de novo Wilson's disease. <i>Neurology</i> , <b>1994</b> , 44, 1079-82	6.5	22

265	Levodopa-carbidopa intrajejunal gel in advanced Parkinson disease with "on" freezing of gait. <i>Neurological Sciences</i> , <b>2015</b> , 36, 1683-6	3.5	21
264	Subthalamic Stimulation Improves Quality of Life of Patients Aged 61 Years or Older With Short Duration of Parkinson's Disease. <i>Neuromodulation</i> , <b>2018</b> , 21, 532-540	3.1	21
263	Therapy-resistant symptoms in Parkinson's disease. <i>Journal of Neural Transmission</i> , <b>2016</b> , 123, 19-30	4.3	21
262	Adherence to anti-Parkinson drug therapy in the "REASON" sample of Italian patients with Parkinson's disease: the linguistic validation of the Italian version of the "Morisky Medical Adherence Scale-8 items". <i>Neurological Sciences</i> , <b>2013</b> , 34, 2015-22	3.5	21
261	Linguistic, psychometric validation and diagnostic ability assessment of an Italian version of a 19-item wearing-off questionnaire for wearing-off detection in Parkinson's disease. <i>Neurological Sciences</i> , <b>2012</b> , 33, 1319-27	3.5	21
260	High-rate production of functional nanostructured films and devices by coupling flame spray pyrolysis with supersonic expansion. <i>Nanotechnology</i> , <b>2012</b> , 23, 185603	3.4	21
259	Continuous dopaminergic stimulation achieved by duodenal levodopa infusion. <i>Neurological Sciences</i> , <b>2008</b> , 29 Suppl 5, S387-8	3.5	21
258	Parkinson's disease, chronic hydrocarbon exposure and striatal neuronal damage: a 1-H MRS study. <i>NeuroToxicology</i> , <b>2006</b> , 27, 164-8	4.4	21
257	Improvement of dyskinesias with L-dopa infusion in advanced Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , <b>2016</b> , 133, 451-8	3.8	21
256	Automated MRI Classification in Progressive Supranuclear Palsy: A Large International Cohort Study. <i>Movement Disorders</i> , <b>2020</b> , 35, 976-983	7	20
255	Relevance of sleep quality on caregiver burden in Parkinson's disease. <i>Neurological Sciences</i> , <b>2018</b> , 39, 835-839	3.5	20
254	Motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study. <i>Neurological Sciences</i> , <b>2016</b> , 37, 1785-1792	3.5	20
253	Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety. <i>Journal of Parkinson's Disease</i> , <b>2019</b> , 9, 531-541	5.3	20
252	Novel levodopa formulations in the treatment of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , <b>2014</b> , 14, 143-9	4.3	20
251	Cohort study of prevalence and phenomenology of tremor in dementia with Lewy bodies. <i>Journal of Neurology</i> , <b>2013</b> , 260, 1731-42	5.5	20
250	The feasibility of statistical parametric mapping for the analysis of positron emission tomography studies using 11C-2-beta-carbomethoxy-3-beta-(4-fluorophenyl)-tropane in patients with movement disorders. <i>Nuclear Medicine Communications</i> , <b>2002</b> , 23, 1047-55	1.6	20
249	Clinical Correlates of Functional Motor Disorders: An Italian Multicenter Study. <i>Movement Disorders Clinical Practice</i> , <b>2020</b> , 7, 920-929	2.2	20
248	Apathy in Mild Parkinson's Disease: Neuropsychological and Neuroimaging Evidence. <i>Journal of Parkinson's Disease</i> , <b>2016</b> , 6, 821-832	5.3	20

247	Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease. <i>Journal of Neural Transmission</i> , <b>2018</b> , 125, 1131-1135	4.3	19
246	Can therapeutic strategies prevent and manage dyskinesia in Parkinson's disease? An update. <i>Expert Opinion on Drug Safety</i> , <b>2019</b> , 18, 1203-1218	4.1	19
245	Successful subthalamic stimulation in genetic Parkinson's disease caused by duplication of the $\beta$ synuclein gene. <i>Journal of Neurology</i> , <b>2012</b> , 259, 165-7	5.5	19
244	Arterial hypertension, a tricky side of Parkinson's disease: physiopathology and therapeutic features. <i>Neurological Sciences</i> , <b>2013</b> , 34, 621-7	3.5	19
243	Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa. <i>European Neuropsychopharmacology</i> , <b>2010</b> , 20, 683-7	1.2	19
242	Brain Amyloid Contribution to Cognitive Dysfunction in Early-Stage Parkinson's Disease: The PPMI Dataset. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 66, 229-237	4.3	19
241	Device-Aided Treatment Strategies in Advanced Parkinson's Disease. <i>International Review of Neurobiology</i> , <b>2017</b> , 132, 453-474	4.4	18
240	Multiple system atrophy as emerging template for accelerated drug discovery in $\beta$ synucleinopathies. <i>Parkinsonism and Related Disorders</i> , <b>2014</b> , 20, 793-9	3.6	18
239	An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients. <i>Advances in Therapy</i> , <b>2017</b> , 34, 1741-1752	4.7	18
238	Nigral anatomy and striatal denervation in genetic Parkinsonism: A family report. <i>Movement Disorders</i> , <b>2015</b> , 30, 1148-9	7	18
237	Overground robot assisted gait trainer for the treatment of drug-resistant freezing of gait in Parkinson disease. <i>Journal of the Neurological Sciences</i> , <b>2015</b> , 355, 75-8	3.2	18
236	Pharmacological and PET studies in patient's with Parkinson's disease and a short duration-motor response: implications in the pathophysiology of motor complications. <i>Journal of Neural Transmission</i> , <b>2004</b> , 111, 497-509	4.3	18
235	Infusion of nerve growth factor (NGF) into kitten visual cortex increases immunoreactivity for NGF, NGF receptors, and choline acetyltransferase in basal forebrain without affecting ocular dominance plasticity or column development. <i>Neuroscience</i> , <b>2001</b> , 108, 569-85	3.9	18
234	Heart rate circadian profile in the differential diagnosis between Parkinson disease and multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , <b>2014</b> , 20, 217-21	3.6	17
233	The End Is the Beginning: Parkinson's Disease in the Light of Brain Imaging. <i>Frontiers in Aging Neuroscience</i> , <b>2017</b> , 9, 330	5.3	17
232	Deep brain stimulation for the treatment of Parkinson's disease: the experience of the Neurosurgical Department in Monza. <i>Neurological Sciences</i> , <b>2003</b> , 24 Suppl 1, S43-4	3.5	17
231	Feasibility and Utility of mHealth for the Remote Monitoring of Parkinson Disease: Ancillary Study of the PD_manager Randomized Controlled Trial. <i>JMIR MHealth and UHealth</i> , <b>2020</b> , 8, e16414	5.5	17
230	Beneficial nonmotor effects of subthalamic and pallidal neurostimulation in Parkinson's disease. <i>Brain Stimulation</i> , <b>2020</b> , 13, 1697-1705	5.1	17

229	Acceptability to patients, carers and clinicians of an mHealth platform for the management of Parkinson's disease (PD_Manager): study protocol for a pilot randomised controlled trial. <i>Trials</i> , <b>2018</b> , 19, 492	2.8	17
228	Relationship between pain and motor and non-motor symptoms in Parkinson's disease. <i>European Journal of Neurology</i> , <b>2017</b> , 24, 974-980	6	16
227	A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson's disease: results at the 36-month follow-up. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2020</b> , 91, 687-694	5.5	16
226	Monitoring of motor and non-motor symptoms of Parkinson's disease through a mHealth platform. <i>Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference</i> , <b>2016</b> , 2016, 663-666	0.9	16
225	Understanding and Treating Pain Syndromes in Parkinson's Disease. <i>International Review of Neurobiology</i> , <b>2017</b> , 134, 827-858	4.4	16
224	Observational study of sleep-related disorders in Italian patients with Parkinson's disease: usefulness of the Italian version of Parkinson's disease sleep scale. <i>Neurological Sciences</i> , <b>2012</b> , 33, 689-945	3.5	16
223	What is the best treatment for fluctuating Parkinson's disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?. <i>Journal of Neural Transmission</i> , <b>2011</b> , 118, 907-14	4.3	16
222	Continuous dopaminergic delivery in Parkinson's disease. <i>Journal of Neurology</i> , <b>2010</b> , 257, S305-8	5.5	16
221	Striatal dopaminergic denervation in early and late onset Parkinson's disease assessed by PET and the tracer [11C]FECIT: preliminary findings in one patient with autosomal recessive parkinsonism (Park2). <i>Neurological Sciences</i> , <b>2002</b> , 23 Suppl 2, S51-2	3.5	16
220	Brain flow changes before and after deep brain stimulation of the subthalamic nucleus in Parkinson's disease. <i>Neurological Sciences</i> , <b>2003</b> , 24, 151-2	3.5	16
219	A procedure for the simultaneous visualization of two anterograde and different retrograde fluorescent tracers. Application to the study of the afferent-efferent organization of thalamic anterior intralaminar nuclei. <i>Journal of Neuroscience Methods</i> , <b>1991</b> , 38, 183-91	3	16
218	Differences in binocular interactions between cortical areas 17 and 18 and superior colliculus of Siamese cats. <i>Journal of Comparative Neurology</i> , <b>1981</b> , 200, 597-611	3.4	16
217	The Non-Motor Symptoms Scale in Parkinson's disease: Validation and use. <i>Acta Neurologica Scandinavica</i> , <b>2021</b> , 143, 3-12	3.8	16
216	Targeting pain in Parkinson's disease. <i>Lancet Neurology, The</i> , <b>2015</b> , 14, 1144-5	24.1	15
215	Idiopathic delayed-onset edema surrounding deep brain stimulation leads: Insights from a case series and systematic literature review. <i>Parkinsonism and Related Disorders</i> , <b>2016</b> , 32, 108-115	3.6	15
214	Adenosine A2A receptor antagonists in Parkinson's disease: still in the running. <i>Lancet Neurology, The</i> , <b>2014</b> , 13, 748-9	24.1	15
213	Validation of the Italian version of Parkinson's disease-cognitive rating scale (PD-CRS). <i>Neurological Sciences</i> , <b>2014</b> , 35, 537-44	3.5	15
212	Cognitive impairment in multiple system atrophy. <i>Movement Disorders</i> , <b>2017</b> , 32, 1338-1339	7	15

211	Validation and attempts of revision of the MDS-recommended tests for the screening of Parkinson's disease dementia. <i>Parkinsonism and Related Disorders</i> , <b>2014</b> , 20, 32-6	3.6	15
210	Pulsatile or continuous dopaminomimetic strategies in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2012</b> , 18 Suppl 1, S120-2	3.6	15
209	Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders. <i>Neurological Sciences</i> , <b>2012</b> , 33, 585-93	3.5	15
208	Pharmacokinetic evaluation of pramipexole. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2011</b> , 7, 1307-14	5.5	15
207	Regression of cardiac valvulopathy related to ergot-derived dopamine agonists. <i>Cardiovascular Therapeutics</i> , <b>2011</b> , 29, 404-10	3.3	15
206	Multifocal alterations of white matter accompany the transition from normal cognition to dementia in Parkinson's disease patients. <i>Brain Imaging and Behavior</i> , <b>2019</b> , 13, 232-240	4.1	15
205	Deep brain stimulation for monogenic Parkinson's disease: a systematic review. <i>Journal of Neurology</i> , <b>2020</b> , 267, 883-897	5.5	15
204	Dysphagia predicts poor outcome in late-stage Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2019</b> , 64, 73-81	3.6	14
203	Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2019</b> , 11, 301-309	5.2	14
202	The Progressive Supranuclear Palsy Clinical Deficits Scale. <i>Movement Disorders</i> , <b>2020</b> , 35, 650-661	7	14
201	Reasons driving treatment modification in Parkinson's disease: results from the cross-sectional phase of the REASON study. <i>Parkinsonism and Related Disorders</i> , <b>2013</b> , 19, 1130-5	3.6	14
200	Lithiated MnO <sub>2</sub> Phases as Cathodes for 3 V Li and Li-Ion Cells. <i>Journal of the Electrochemical Society</i> , <b>1997</b> , 144, 1553-1559	3.9	14
199	Positron emission tomography in drug evaluation: influence of three different catechol-O-methyltransferase inhibitors on metabolism of [NCA] 6-[18F]fluoro-L-dopa in rhesus monkey. <i>Nuclear Medicine and Biology</i> , <b>1995</b> , 22, 921-7	2.1	14
198	Behavioral and electrophysiological effects of unilateral optic tract section in ordinary and Siamese cats. <i>Journal of Comparative Neurology</i> , <b>1979</b> , 185, 183-202	3.4	14
197	Application of the '5-2-1' screening criteria in advanced Parkinson's disease: interim analysis of DUOGLOBE. <i>Neurodegenerative Disease Management</i> , <b>2020</b> , 10, 309-323	2.8	14
196	Functional motor disorders associated with other neurological diseases: Beyond the boundaries of "organic" neurology. <i>European Journal of Neurology</i> , <b>2021</b> , 28, 1752-1758	6	14
195	First comprehensive tool for screening pain in Parkinson's disease: the King's Parkinson's Disease Pain Questionnaire. <i>European Journal of Neurology</i> , <b>2018</b> , 25, 1255-1261	6	14
194	Benzodiazepine receptor binding in Huntington's disease: [11C]flumazenil uptake measured using positron emission tomography. <i>Annals of Neurology</i> , <b>2000</b> , 47, 644-8	9.4	14

193	Immunization therapies for Parkinson's disease: state of the art and considerations for future clinical trials. <i>Expert Opinion on Investigational Drugs</i> , <b>2020</b> , 29, 685-695	5.9	13
192	The PRIAMO study: active sexual life is associated with better motor and non-motor outcomes in men with early Parkinson's disease. <i>European Journal of Neurology</i> , <b>2019</b> , 26, 1327-1333	6	13
191	Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson's disease: implications for patients. <i>Neuropsychiatric Disease and Treatment</i> , <b>2011</b> , 7, 297-302	3.1	13
190	Single-photon emission computed tomography in diagnosis and differential diagnosis of Parkinson's disease. <i>Neurodegenerative Diseases</i> , <b>2010</b> , 7, 319-29	2.3	13
189	[123I]FP-CIT SPECT findings in two patients with Hallervorden-Spatz disease with homozygous mutation in PANK2 gene. <i>Neurology</i> , <b>2005</b> , 64, 167-8	6.5	13
188	Factors shaping the corpus callosum. <i>Journal of Comparative Neurology</i> , <b>2001</b> , 433, 437-40	3.4	13
187	Tuning AlAs-GaAs heterostructure properties by means of MBE-grown Si interface layers. <i>Surface Science</i> , <b>1991</b> , 251-252, 82-86	1.8	13
186	Immediate postoperative retention of visual discriminations following selective cortical lesions in the cat. <i>Behavioural Brain Research</i> , <b>1985</b> , 17, 145-62	3.4	13
185	Foot Pressure Wearable Sensors for Freezing of Gait Detection in Parkinson's Disease. <i>Sensors</i> , <b>2020</b> , 21,	3.8	13
184	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group. <i>Movement Disorders Clinical Practice</i> , <b>2020</b> , 7, 750-762	2.2	13
183	Levodopa-carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry. <i>Neurodegenerative Disease Management</i> , <b>2019</b> , 9, 39-46	2.8	13
182	Burden of non-motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa-carbidopa intestinal gel. <i>European Journal of Neurology</i> , <b>2019</b> , 26, 581-e43	6	13
181	Acute response of non-motor symptoms to subthalamic deep brain stimulation in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2017</b> , 41, 113-117	3.6	12
180	Long-term effect of subthalamic and pallidal deep brain stimulation for status dystonicus in children with methylmalonic acidemia and GNAO1 mutation. <i>Journal of Neural Transmission</i> , <b>2019</b> , 126, 739-757	4.3	12
179	Anatomy and Connectivity of the Subthalamic Nucleus in Humans and Non-human Primates. <i>Frontiers in Neuroanatomy</i> , <b>2020</b> , 14, 13	3.6	12
178	Beneficial effect of 24-month bilateral subthalamic stimulation on quality of sleep in Parkinson's disease. <i>Journal of Neurology</i> , <b>2020</b> , 267, 1830-1841	5.5	12
177	Age/disease duration influence on activities of daily living and quality of life after levodopa-carbidopa intestinal gel in Parkinson's disease. <i>Neurodegenerative Disease Management</i> , <b>2018</b> , 8, 161-170	2.8	12
176	Characteristics and progression of cognitive deficits in progressive supranuclear palsy vs. multiple system atrophy and Parkinson's disease. <i>Journal of Neural Transmission</i> , <b>2019</b> , 126, 1437-1445	4.3	12

175	Clinical experiences with levodopa methylester (melevodopa) in patients with Parkinson disease experiencing motor fluctuations: an open-label observational study. <i>Clinical Neuropharmacology</i> , <b>2010</b> , 33, 61-6	1.4	12
174	MoSi2 laminate processed by tape casting: Microstructure and mechanical properties' investigation. <i>Intermetallics</i> , <b>2008</b> , 16, 758-768	3.5	12
173	Cerebral activity modulation by extradural motor cortex stimulation in Parkinson's disease: a perfusion SPECT study. <i>European Journal of Neurology</i> , <b>2008</b> , 15, 22-8	6	12
172	The rationale for improved integration between home care and neurology hospital services in patients with advanced Parkinson's disease. <i>Neurological Sciences</i> , <b>2008</b> , 29 Suppl 5, S392-6	3.5	12
171	Relationship of Nocturnal Sleep Dysfunction and Pain Subtypes in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , <b>2019</b> , 6, 57-64	2.2	12
170	Frontal and subcortical contribution to visual hallucinations in dementia with Lewy bodies and Parkinson's disease. <i>Postgraduate Medicine</i> , <b>2019</b> , 131, 509-522	3.7	11
169	The neural correlates of spatial and object working memory in elderly and Parkinson's disease subjects. <i>Behavioural Neurology</i> , <b>2015</b> , 2015, 123636	3	11
168	"Gunslinger's gait": a new cause of unilaterally reduced arm swing. <i>BMJ, The</i> , <b>2015</b> , 351, h6141	5.9	11
167	Dermoscopic features and follow-up changes of acral melanocytic naevi in childhood and adolescence. <i>British Journal of Dermatology</i> , <b>2014</b> , 170, 374-81	4	11
166	Validation of a home environment test battery for supporting assessments in advanced Parkinson's disease. <i>Neurological Sciences</i> , <b>2012</b> , 33, 831-8	3.5	11
165	The possible clinical predictors of fatigue in Parkinson's disease: a study of 135 patients as part of international nonmotor scale validation project. <i>Parkinson's Disease</i> , <b>2011</b> , 2011, 125271	2.6	11
164	The effect of repeated administrations of granulocyte colony stimulating factor for blood stem cells mobilization in patients with progressive supranuclear palsy, corticobasal degeneration and multiple system atrophy. <i>Clinical Neurology and Neurosurgery</i> , <b>2010</b> , 112, 65-7	2	11
163	Clinical and imaging characterization of a patient with idiopathic progressive ataxia and palatal tremor. <i>European Journal of Neurology</i> , <b>2007</b> , 14, 944-6	6	11
162	New strategies in motor parkinsonism. <i>Parkinsonism and Related Disorders</i> , <b>2007</b> , 13 Suppl 3, S446-9	3.6	11
161	Radiosynthesis of [11C]brofaromine, a potential tracer for imaging monoamine oxidase A. <i>Nuclear Medicine and Biology</i> , <b>1996</b> , 23, 229-34	2.1	11
160	Electrophysiological evidence for interhemispheric connections in the anterior ectosylvian sulcus in the cat. <i>Experimental Brain Research</i> , <b>1987</b> , 66, 90-8	2.3	11
159	Technology-Enabled Care: Integrating Multidisciplinary Care in Parkinson's Disease Through Digital Technology. <i>Frontiers in Neurology</i> , <b>2020</b> , 11, 575975	4.1	11
158	A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study. <i>Movement Disorders</i> , <b>2021</b> , 36, 681-689	7	11

157	The PRIAMO study: age- and sex-related relationship between prodromal constipation and disease phenotype in early Parkinson's disease. <i>Journal of Neurology</i> , <b>2021</b> , 268, 448-454	5.5	11
156	Tremor UPDRS estimation in home environment. <i>Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference</i> , <b>2016</b> , 2016, 3642-3645	0.9	10
155	A decision support system for Parkinson disease management: expert models for suggesting medication change. <i>Journal of Decision Systems</i> , <b>2018</b> , 27, 164-172	1.2	10
154	Validity and metric of MiniMental Parkinson and MiniMental State Examination in Parkinson's disease. <i>Neurological Sciences</i> , <b>2013</b> , 34, 1751-8	3.5	10
153	Apomorphine and levodopa infusion therapies for advanced Parkinson's disease. <i>Journal of Movement Disorders</i> , <b>2009</b> , 2, 4-9	2.9	10
152	Cerebral 6-[18F]fluoro-L-DOPA uptake in rhesus monkey: pharmacological influence of aromatic amino acid decarboxylase (AAAD) and catechol-O-methyltransferase (COMT) inhibition. <i>Brain Research</i> , <b>1997</b> , 767, 45-54	3.7	10
151	Savoxepine: striatal dopamine-D2 receptor occupancy in human volunteers measured using positron emission tomography (PET). <i>European Journal of Clinical Pharmacology</i> , <b>1993</b> , 44, 135-40	2.8	10
150	Subthalamic Stimulation Improves Quality of Sleep in Parkinson Disease: A 36-Month Controlled Study. <i>Journal of Parkinsons Disease</i> , <b>2021</b> , 11, 323-335	5.3	10
149	Personalised Advanced Therapies in Parkinson's Disease: The Role of Non-Motor Symptoms Profile. <i>Journal of Personalized Medicine</i> , <b>2021</b> , 11,	3.6	10
148	Parkinson disease: Can dopamine transporter imaging define early PD?. <i>Nature Reviews Neurology</i> , <b>2014</b> , 10, 432-3	15	9
147	Patients with rest-tremor and scans with ipsilateral dopaminergic deficit. <i>Journal of Neurology</i> , <b>2013</b> , 260, 1132-5	5.5	9
146	A Pilot Prospective, Multicenter Observational Study of Dopamine Agonist Withdrawal Syndrome in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , <b>2015</b> , 2, 170-174	2.2	9
145	Exploring composites based on PPO blend as ablative thermal protection systems [Part II: The role of equiaxial fillers. <i>Composite Structures</i> , <b>2012</b> , 94, 1060-1066	5.3	9
144	Sleep in genetically confirmed pantothenate kinase-associated neurodegeneration: a video-polysomnographic study. <i>Parkinsons Disease</i> , <b>2010</b> , 2010, 342834	2.6	9
143	Imaging for early differential diagnosis of parkinsonism. <i>Lancet Neurology</i> , <b>The</b> , <b>2010</b> , 9, 130-1	24.1	9
142	Long-term intracerebral infusion of fibroblast growth factors restores motility and enhances F-DOPA uptake in parkinsonian monkeys. <i>Parkinsonism and Related Disorders</i> , <b>1998</b> , 4, 147-58	3.6	9
141	Moving towards home-based community-centred integrated care in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2020</b> , 78, 21-26	3.6	9
140	The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review. <i>Advances in Therapy</i> , <b>2021</b> , 38, 2854-2890	4.1	9



139	Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease. <i>Npj Parkinsons Disease</i> , <b>2021</b> , 7, 48	9.7	9
138	Globus pallidus internus deep brain stimulation for the treatment of status dystonicus in tardive dystonia. <i>Acta Neurochirurgica</i> , <b>2016</b> , 158, 1789-91	3	9
137	Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET. <i>Clinical Neuropharmacology</i> , <b>1999</b> , 22, 277-80	1.4	9
136	Functional neuroimaging (PET and SPECT) in the selection and assessment of patients with Parkinson's disease undergoing deep brain stimulation. <i>Journal of Neurosurgical Sciences</i> , <b>2003</b> , 47, 40-6	1.3	9
135	Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders. <i>Functional Neurology</i> , <b>2010</b> , 25, 21-5	2.2	9
134	Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias. <i>Expert Review of Neurotherapeutics</i> , <b>2015</b> , 15, 207-13	4.3	8
133	Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson's disease patients: an European multicentre survey. <i>Journal of Neural Transmission</i> , <b>2020</b> , 127, 875-879	4.3	8
132	The MTHFR C677T polymorphism modifies age at onset in Parkinson's disease. <i>Neurological Sciences</i> , <b>2014</b> , 35, 73-7	3.5	8
131	Cerebral metabolic changes (18F-FDG PET) during selective anterior temporal lobe amobarbital test. <i>European Neurology</i> , <b>1997</b> , 38, 268-75	2.1	8
130	Striatal dopamine transporter binding in patients with Parkinson's disease and severe occupational hydrocarbon exposure. <i>European Journal of Neurology</i> , <b>2007</b> , 14, 297-9	6	8
129	Clinical utility of DaTscan in patients with suspected Parkinsonian syndrome: a systematic review and meta-analysis. <i>Npj Parkinsons Disease</i> , <b>2021</b> , 7, 43	9.7	8
128	Apomorphine infusion in advanced Parkinson disease. <i>Nature Reviews Neurology</i> , <b>2018</b> , 14, 693-694	15	8
127	MRI indirect stereotactic targeting for deep brain stimulation in Parkinson's disease. <i>Journal of Neurosurgical Sciences</i> , <b>2003</b> , 47, 26-32	1.3	8
126	Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?. <i>ENeurologicalSci</i> , <b>2017</b> , 8, 44-53	2.1	7
125	Nonmotor Symptoms and Natural History of Parkinson's Disease: Evidence From Cognitive Dysfunction and Role of Noninvasive Interventions. <i>International Review of Neurobiology</i> , <b>2017</b> , 133, 389-415	4.4	7
124	Pathological gambling in Parkinson's disease: disease related or drug related?. <i>Expert Review of Neurotherapeutics</i> , <b>2011</b> , 11, 809-14	4.3	7
123	Cognitive bizarreness in the dream and waking mentation of nonpsychotic patients with Parkinson's disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , <b>2010</b> , 22, 395-400	2.7	7
122	Geometrically Nonlinear Cantilever under Stochastic Loading Vectors. <i>Nonlinear Dynamics</i> , <b>2002</b> , 28, 83-102	5	7

121	Effects of terguride in patients with Huntington's disease. <i>Clinical Neuropharmacology</i> , <b>1989</b> , 12, 435-9	1.4	7
120	The role of I-ioflupane SPECT dopamine transporter imaging in the diagnosis and treatment of patients with dementia with Lewy bodies. <i>Neuropsychiatric Disease and Treatment</i> , <b>2007</b> , 3, 287-92	3.1	7
119	The impact of COVID-19 on palliative care for people with Parkinson's and response to future pandemics. <i>Expert Review of Neurotherapeutics</i> , <b>2021</b> , 21, 615-623	4.3	7
118	Dopaminergic Medication Modulates Learning from Feedback and Error-Related Negativity in Parkinson's Disease: A Pilot Study. <i>Frontiers in Behavioral Neuroscience</i> , <b>2016</b> , 10, 205	3.5	7
117	Impact of Cognitive Profile on Impulse Control Disorders Presence and Severity in Parkinson's Disease. <i>Frontiers in Neurology</i> , <b>2019</b> , 10, 266	4.1	6
116	Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving 2000 mg Daily Dose of Levodopa. <i>Parkinson's Disease</i> , <b>2020</b> , 2020, 9716317	2.6	6
115	Bilateral subthalamic deep brain stimulation in a patient with Parkinson's disease who had previously undergone thalamotomy and autologous adrenal grafting in the caudate nucleus: case report. <i>Neurosurgery</i> , <b>2006</b> , 59, E1140; discussion E1140	3.2	6
114	Indoor Exposure in a Region of Central Italy. <i>Radiation Protection Dosimetry</i> , <b>1984</b> , 7, 271-274	0.9	6
113	Differences in cognitive profiles between Lewy body and Parkinson's disease dementia. <i>Journal of Neural Transmission</i> , <b>2020</b> , 127, 323-330	4.3	6
112	Impact of social and mobility restrictions in Parkinson's disease during COVID-19 lockdown. <i>BMC Neurology</i> , <b>2021</b> , 21, 332	3.1	6
111	Comment on "The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis". <i>Otolaryngology - Head and Neck Surgery</i> , <b>2020</b> , 163, 852	5.5	5
110	Effects of rotigotine on Parkinson's disease-related sleep disturbances. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 2571-80	4	5
109	Clinical variables associated with treatment changes in Parkinson's disease: results from the longitudinal phase of the REASON study. <i>Neurological Sciences</i> , <b>2015</b> , 36, 935-43	3.5	5
108	Handbook of Non-Motor Symptoms in Parkinson's Disease <b>2011</b> ,		5
107	Cortical visual evoked potentials recorded after optic tract near field stimulation during GPI-DBS in non-cooperative patients. <i>Clinical Neurology and Neurosurgery</i> , <b>2011</b> , 113, 119-22	2	5
106	Low scan rate DSC study of the monoclinic-tetragonal transition in zirconia. <i>Thermochimica Acta</i> , <b>2011</b> , 524, 18-22	2.9	5
105	Clinical experience of tolcapone in advanced Parkinson's disease. <i>Neurological Sciences</i> , <b>2008</b> , 29 Suppl 5, S380-2	3.5	5
104	Side effects of the catechol-O-methyl-transferase inhibitor Ro 40-7592 in rabbits. <i>Clinical Neuropharmacology</i> , <b>1994</b> , 17, 270-6	1.4	5

103	Blood to brain iron uptake in one rhesus monkey using [Fe-52]-citrate and positron emission tomography (PET): influence of haloperidol. <i>Journal of Neural Transmission Supplementum</i> , <b>1994</b> , 43, 123-32		5
102	Psychometric properties of the Italian version of the Scales for Outcomes in Parkinson's disease-Cognition (SCOPA-Cog). <i>Functional Neurology</i> , <b>2013</b> , 28, 121-5	2.2	5
101	Dysphagia in multiple system atrophy consensus statement on diagnosis, prognosis and treatment. <i>Parkinsonism and Related Disorders</i> , <b>2021</b> , 86, 124-132	3.6	5
100	Dopamine Receptors in Parkinson's Disease: A Meta-Analysis of Imaging Studies. <i>Movement Disorders</i> , <b>2021</b> , 36, 1781-1791	7	5
99	Comparison of self-reported symptoms and psychophysical tests in coronavirus disease 2019 (COVID-19) subjects experiencing long-term olfactory dysfunction: a 6-month follow-up study. <i>International Forum of Allergy and Rhinology</i> , <b>2021</b> , 11, 1592-1595	6.3	5
98	The contribution of beta-amyloid to dementia in Lewy body diseases: a 1-year follow-up study. <i>Brain Communications</i> , <b>2021</b> , 3, fcab180	4.5	5
97	Deep brain stimulation in Parkinson's disease: A multicentric, long-term, observational pilot study. <i>Journal of the Neurological Sciences</i> , <b>2019</b> , 405, 116411	3.2	4
96	DBS for Parkinson's disease with behavioural disturbances. <i>Lancet Neurology</i> , <b>2018</b> , 17, 195-197	24.1	4
95	Is there room for new non-dopaminergic treatments in Parkinson's disease?. <i>Journal of Neural Transmission</i> , <b>2013</b> , 120, 349-52	4.3	4
94	Single photon-emission computed tomography imaging in early Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , <b>2008</b> , 8, 1853-64	4.3	4
93	Daytime somnolence and night sleep disturbances in Parkinson's disease: background and future treatment prospective. <i>Neurological Sciences</i> , <b>2007</b> , 28 Suppl 1, S6-8	3.5	4
92	Mössbauer study of the Pb <sub>x</sub> Sn <sub>1-x</sub> 125Te system. <i>Physica Status Solidi (B): Basic Research</i> , <b>1982</b> , 114, 585-588	1.3	4
91	Efficacy, safety and patient's quality of life of long-term treatment with levodopa-carbidopa intestinal gel in advanced Parkinson's disease in Romania: Results from GLORIA observational study <b>2020</b> , 19, 27-35		4
90	Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications. <i>Parkinsonism and Related Disorders</i> , <b>2021</b> , 92, 59-66	3.6	4
89	Incentive-driven decision-making networks in de novo and drug-treated Parkinson's disease patients with impulsive-compulsive behaviors: A systematic review of neuroimaging studies. <i>Parkinsonism and Related Disorders</i> , <b>2020</b> , 78, 165-177	3.6	4
88	tDCS effect on cognitive performance in Parkinson's disease. <i>Movement Disorders</i> , <b>2016</b> , 31, 1253-4	7	4
87	Access and Attitudes Toward Palliative Care Among Movement Disorders Clinicians. <i>Movement Disorders</i> , <b>2021</b> ,	7	4
86	Impact of Supporting People with Advanced Parkinson's Disease on Carer's Quality of Life and Burden. <i>Neuropsychiatric Disease and Treatment</i> , <b>2020</b> , 16, 2899-2912	3.1	3

85	Risk factors for impulse control disorders and related behaviors in Parkinson's disease: secondary analyses of the ICARUS study. <i>Journal of Drug Assessment</i> , <b>2019</b> , 8, 159-166	1.5	3
84	Intrathecal application of autologous bone marrow cell preparations in Parkinsonian syndromes. <i>Movement Disorders</i> , <b>2012</b> , 27, 1552-5	7	3
83	Rapid onset of efficacy of rasagiline in early Parkinson's disease. <i>Neurological Sciences</i> , <b>2013</b> , 34, 2007-13	3.5	3
82	Predicting rapid progression of Parkinson's Disease at baseline patients evaluation. <i>Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference</i> , <b>2017</b> , 2017, 3898-3901	0.9	3
81	Mössbauer studies of the Umbria archeological clays. <i>Hyperfine Interactions</i> , <b>1986</b> , 29, 1133-1136	0.8	3
80	Radon and radon daughter evaluation in a natural radioactivity survey indoors. <i>Science of the Total Environment</i> , <b>1985</b> , 45, 373-80	10.2	3
79	Non-motor Symptoms in Parkinson's Disease. <i>European Neurological Review</i> , <b>2009</b> , 4, 25	0.5	3
78	Impairment of human dopaminergic neurons at different developmental stages by perfluoro-octanoic acid (PFOA) and differential human brain areas accumulation of perfluoroalkyl chemicals. <i>Environment International</i> , <b>2021</b> , 158, 106982	12.9	3
77	Laboratory-Supported Multiple System Atrophy beyond Autonomic Function Testing and Imaging: A Systematic Review by the MoDiMSA Study Group. <i>Movement Disorders Clinical Practice</i> , <b>2021</b> , 8, 322-340	2.2	3
76	Asymmetric Dopamine Transporter Loss Affects Cognitive and Motor Progression in Parkinson's Disease. <i>Movement Disorders</i> , <b>2021</b> , 36, 2303-2313	7	3
75	Moving towards Integrated and Personalized Care in Parkinson's Disease: A Framework Proposal for Training Parkinson Nurses. <i>Journal of Personalized Medicine</i> , <b>2021</b> , 11,	3.6	3
74	Digital health technology for non-motor symptoms in people with Parkinson's disease: Futile or future?. <i>Parkinsonism and Related Disorders</i> , <b>2021</b> , 89, 186-194	3.6	3
73	Health care for chronic neurological patients after COVID-19. <i>Lancet Neurology</i> , <b>2020</b> , 19, 562-563	24.1	2
72	Predictors of Response for "Off" Time Improvement With Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis of the GLORIA Registry. <i>Frontiers in Neurology</i> , <b>2020</b> , 11, 419	4.1	2
71	The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson's disease patients. <i>Journal of Neural Transmission</i> , <b>2020</b> , 127, 881-891	4.3	2
70	Long-term effectiveness of levodopa-carbidopa intestinal gel on motor and non-motor symptoms in advanced Parkinson's disease: results of the Italian GLORIA patient population. <i>Neurological Sciences</i> , <b>2020</b> , 41, 2929-2937	3.5	2
69	The First Parkinson's Disease Pain Questionnaire (King's PD Pain Quest) [an interim analysis of a multicentre study of the patient's perspective. <i>Parkinsonism and Related Disorders</i> , <b>2016</b> , 22, e41	3.6	2
68	2.135 CHARACTERISING NON MOTOR PATTERNS OF EARLY MORNING OFF PERIODS IN PARKINSON'S DISEASE: AN INTERNATIONAL STUDY. <i>Parkinsonism and Related Disorders</i> , <b>2012</b> , 18, S110	3.6	2

67	DN1 ECONOMIC EVALUATION OF SPECT-DATSCAN IN THE DIAGNOSIS OF PATIENTS WITH CLINICALLY UNCERTAIN PARKINSONISM IN ITALY. <i>Value in Health</i> , <b>2005</b> , 8, A14	3.3	2
66	Mössbauer Study of the Pb <sub>x</sub> Sn Te System. <i>Physica Status Solidi (B): Basic Research</i> , <b>1983</b> , 120, K15-K18	1.3	2
65	Repetitive transcranial magnetic stimulation in the treatment of dystonia <b>2012</b> , 501-511		2
64	Education on palliative care for Parkinson patients: development of the "Best care for people with late-stage Parkinson's disease" curriculum toolkit. <i>BMC Medical Education</i> , <b>2021</b> , 21, 538	3.3	2
63	Brain Networks of Motor Behavior Assessed by Principal Component Analysis <b>1998</b> , 165-172		2
62	Reproducibility of Regional Metabolic Covariance Patterns: Comparison of Four Populations <b>1998</b> , 247-252		2
61	Prevalence of Extrapyrarnidal Symptoms in In-Patients With Severe Mental Illnesses: Focus on Parkinsonism. <i>Frontiers in Neurology</i> , <b>2020</b> , 11, 593143	4.1	2
60	Oscillatory EEG-TMS Reactivity in Parkinson Disease. <i>Journal of Clinical Neurophysiology</i> , <b>2021</b> ,	2.2	2
59	Reply to: "Parkinson disease-associated dyskinesia in countries with low access to levodopa-sparing Regimens". <i>Movement Disorders</i> , <b>2019</b> , 34, 1930-1931	7	2
58	Patients Stratification Strategies to Optimize the Effectiveness of Scavenging Biogenic Aldehydes: Towards a Neuroprotective Approach for Parkinson's Disease. <i>Current Neuropharmacology</i> , <b>2021</b> , 19, 1618-1639	7.6	2
57	Advance Care Planning and Care Coordination for People With Parkinson's Disease and Their Family Caregivers-Study Protocol for a Multicentre, Randomized Controlled Trial. <i>Frontiers in Neurology</i> , <b>2021</b> , 12, 673893	4.1	2
56	The Parkinson's Real-World Impact Assessment (PRISM) Study: A European Survey of the Burden of Parkinson's Disease in Patients and their Carers. <i>Journal of Parkinson's Disease</i> , <b>2021</b> , 11, 1309-1323	5.3	2
55	Consensus on the treatment of dysphagia in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , <b>2021</b> , 430, 120008	3.2	2
54	Reduced Effective Connectivity in the Motor Cortex in Parkinson's Disease. <i>Brain Sciences</i> , <b>2021</b> , 11,	3.4	2
53	Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy-Parkinsonism From Parkinson's Disease.. <i>Movement Disorders</i> , <b>2022</b> ,	7	2
52	Dyskinesia Matters: But Not as Much as It Used to. <i>Movement Disorders</i> , <b>2020</b> , 35, 900-901	7	1
51	Reply: Dynamic functional connectivity changes in Lewy body disease. <i>Brain</i> , <b>2019</b> , 142, e69	11.2	1
50	Dopaminergic treatment and nonmotor features of Parkinson disease: the horse lives. <i>Neurology</i> , <b>2013</b> , 81, 854	6.5	1

49	The conundrum of neuroprotection in Parkinson's disease. <i>Lancet Neurology, The</i> , <b>2011</b> , 10, 396-7	24.1	1
48	Bioactive Sulforaphane from in vitro Propagated Brassica Seedlings. <i>Engineering in Life Sciences</i> , <b>2007</b> , 7, 275-277	3.4	1
47	Channeling-based collimators for generation of microbeams produced by silicon micromachining technology. <i>Nuclear Instruments &amp; Methods in Physics Research B</i> , <b>2006</b> , 252, 11-15	1.2	1
46	Morbo di Parkinson, esposizione a sostanze tossiche e nuclei della base Uno studio mediante spettroscopia protonica a risonanza magnetica. <i>The Neuroradiology Journal</i> , <b>2001</b> , 14, 47-48		1
45	Subthalamic deep brain stimulation in Parkinson's disease with SNCA mutations: Based on the follow-up to 10 years.. <i>Brain and Behavior</i> , <b>2022</b> , e2503	3.4	1
44	Does the 5-2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries.. <i>BMC Neurology</i> , <b>2022</b> , 22, 35	3.1	1
43	Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson's Disease: Real-World Evidence From G7 Countries.. <i>Neurology and Therapy</i> , <b>2022</b> , 11, 303	4.6	1
42	Remote Evaluation of Parkinson's Disease Using a Conventional Webcam and Artificial Intelligence.. <i>Frontiers in Neurology</i> , <b>2021</b> , 12, 742654	4.1	1
41	High Energy Resolution Photoemission Beam Line at ELETTRA. <i>Acta Physica Polonica A</i> , <b>1994</b> , 86, 487-495.6		1
40	Evaluation of cefepime kinetic variables and milk production volume in goats. <i>Arquivo Brasileiro De Medicina Veterinaria E Zootecnia</i> , <b>2004</b> , 56, 116-118	0.3	1
39	Feasibility and Utility of mHealth for the Remote Monitoring of Parkinson Disease: Ancillary Study of the PD_manager Randomized Controlled Trial (Preprint)		1
38	Peri-electrode edema after bilateral subthalamic deep brain stimulation for Parkinson's disease. <i>Journal of Neurosurgical Sciences</i> , <b>2018</b> , 62, 103-105	1.3	1
37	mHealth Platform for Parkinson's Disease Management. <i>IFMBE Proceedings</i> , <b>2019</b> , 29-35	0.2	1
36	Reply to: "Concerns Raised by Publication of Antonini et al., 'Outcome of Parkinson Disease Patients Affected by Covid-19'". <i>Movement Disorders</i> , <b>2020</b> , 35, 1298	7	1
35	Movement perception of the tonic vibration reflex is abnormal in functional limb weakness. <i>Parkinsonism and Related Disorders</i> , <b>2021</b> , 87, 1-6	3.6	1
34	Design and Development of a Mobile Application to Explore Cognitive Skills in Parkinson's Disease Patients. <i>IFMBE Proceedings</i> , <b>2016</b> , 1150-1155	0.2	1
33	TaSCA, an Agile Survey on Chemosensory Impairments for Self-Monitoring of COVID-19 Patients: A Pilot Study. <i>Frontiers in Neurology</i> , <b>2021</b> , 12, 633574	4.1	1
32	A multinational consensus on dysphagia in Parkinson's disease: screening, diagnosis and prognostic value. <i>Journal of Neurology</i> , <b>2021</b> , 1	5.5	1

31	The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Analysis of BIPARK-I and -II. <i>Frontiers in Neurology</i> , <b>2021</b> , 12, 754016	4.1	○
30	Patient-centred management of Parkinson's disease. <i>Lancet Neurology, The</i> , <b>2020</b> , 19, 887-888	24.1	○
29	Safinamide in the treatment pathway of Parkinson's Disease: a European Delphi Consensus.. <i>Npj Parkinsons Disease</i> , <b>2022</b> , 8, 17	9.7	○
28	Quantification of Brain Amyloid Load in Parkinson's Disease With Mild Cognitive Impairment: A PET/MRI Study.. <i>Frontiers in Neurology</i> , <b>2021</b> , 12, 760518	4.1	○
27	Antiphospholipid-Related Chorea: Two Case Reports and Role of Metabolic Imaging.. <i>Movement Disorders Clinical Practice</i> , <b>2022</b> , 9, 516-521	2.2	○
26	Opicapone versus placebo in the treatment of Parkinson's disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial.. <i>BMC Neurology</i> , <b>2022</b> , 22, 88	3.1	○
25	Level I PD-MCI Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia.. <i>Movement Disorders Clinical Practice</i> , <b>2022</b> , 9, 479-483	2.2	○
24	Gender gap in deep brain stimulation for Parkinson's disease.. <i>Npj Parkinsons Disease</i> , <b>2022</b> , 8, 47	9.7	○
23	Action Selection and Motor Decision Making: Insights from Transcranial Magnetic Stimulation. <i>Brain Sciences</i> , <b>2022</b> , 12, 639	3.4	○
22	Personalized Care in Late-Stage Parkinson Disease: Challenges and Opportunities. <i>Journal of Personalized Medicine</i> , <b>2022</b> , 12, 813	3.6	○
21	Data-assisted differential diagnosis of dementia by deep neural networks using MRI: A study from the European DLB consortium. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e043593	1.2	
20	The reliability of a deep learning model in external memory clinic MRI data: A multi-cohort study. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e042969	1.2	
19	Italian survey on intraduodenal levodopa gel treatment in advanced Parkinson disease: State of the art 10 years after marketing. <i>Parkinsonism and Related Disorders</i> , <b>2016</b> , 22, e97-e98	3.6	
18	Movement disorders: towards new therapies in Parkinson's disease. <i>Lancet Neurology, The</i> , <b>2012</b> , 11, 7-8	24.1	
17	Movement disorders in multiple sclerosis268-278		
16	The impact of neuropsychiatric symptoms on quality of life in Parkinson's disease255-260		
15	Bladder Dysfunction <b>2011</b> , 67-72		
14	SPECT Imaging in Movement Disorders <b>2010</b> , 140-147		

- 13 "How many Parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire" by Morgante L, Morgante F, Moro E, et al., published online 7 March 2007. *Parkinsonism and Related Disorders*, **2008**, 14, 264-5; author reply 266-7 3.6
- 12 Early Compensatory Mechanisms in LRRK2 Mutation Carriers.. *Movement Disorders*, **2022**, 7
- 11 Role of Callosal Connections in the Representation of the Visual Field in the Primary Visual Cortex of the Cat **1987**, 349-366
- 10 Lisuride and [C-11]-Raclopride Interaction at the D2 Receptor Site **1995**, 205-214
- 9 Neutral Amino Acids Influence [18F]Fluorodopa Quantification **1998**, 379-385
- 8 Role of Callosal Connections in the Representation of the Visual Field in the Primary Visual Cortex of the Cat **1987**, 349-366
- 7 New routes of dopaminergic drug delivery in patients with Parkinson's disease. *Lancet Neurology, The*, **2020**, 19, 105-106 24.1
- 6 Influence of disease severity in the efficacy response of Parkinson's disease patients with motor fluctuations: Post-hoc analysis from combined BIPARK-I and II. *Journal of the Neurological Sciences*, **2019**, 405, 211 3.2
- 5 Efficacy of opicapone in Parkinson's disease patients according to baseline presence of dyskinesia: A post-hoc analysis from combined BIPARK-I and II. *Journal of the Neurological Sciences*, **2019**, 405, 192 3.2
- 4 Influence of motor fluctuations duration, levodopa dose and duration of use in efficacy responses of Parkinson's disease patients: Post-hoc analysis from combined BIPARK-I and II. *Journal of the Neurological Sciences*, **2019**, 405, 203 3.2
- 3 Reply to: "Experience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsy". *Movement Disorders*, **2021**, 36, 2208-2209 7
- 2 Fractal Analysis of Lower Back Acceleration Profiles in balance tasks. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference*, **2021**, 2021, 7381-7384 0.9
- 1 Spotlight on non-motor symptoms and Covid-19. *International Review of Neurobiology*, **2022**, 4.4